Prescient Therapeutics: Raises $6.5M share purchase plan
- Clinical stage oncology company Prescient Therapeutics (PTX) is looking to raise $6.5 million via a share purchase plan (SPP)
- The clinical-stage oncology company said the funds will support its various clinical and preclinical programs as well as provide working capital
- New shares will offered at an issue price of 5.5 cents which represents a 15 per cent discount to the 10-day volume-weighted average price
- Then the SPP underwritten to $4 million by Viriathus Capital and will open on July 28
- Prescient expects new shares will also issued on August 24 and begin trading on August 26
- PTX shares finished today’s session 13.6 per cent lower at 5.7 cents
